Atara Biotherapeutics, Inc.
ATRA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | -0.00 | 0.05 | 0.13 |
| FCF Yield | -7.77% | -44.01% | -17.26% | -6.57% |
| EV / EBITDA | 25.76 | 3.20 | -15.20 | -3.29 |
| Quality | ||||
| ROIC | 14.29% | 91.37% | -516.74% | -130.69% |
| Gross Margin | 96.85% | 79.18% | 79.25% | 81.08% |
| Cash Conversion Ratio | 2.27 | -3.07 | -0.74 | 1.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 222.20% | 201.81% | 51.46% | 26.58% |
| Free Cash Flow Growth | 73.99% | -14.56% | -515.72% | 62.63% |
| Safety | ||||
| Net Debt / EBITDA | -0.41 | 1.63 | -1.77 | -0.18 |
| Interest Coverage | 3.29 | 38.15 | -12.00 | -18.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.64 | 0.54 |
| Cash Conversion Cycle | -286.25 | 2.04 | 87.36 | 143.09 |